GlassScriptPhysician profile
David A Kiken
NPI 1801004114
$4,732.65
in general payments reported to CMS, 2019-2025
20 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $642 · 2021: $709 · 2022: $931 · 2023: $515 · 2024: $598 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780 · Education: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.28 |
| Education | $444.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,253.72 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Galderma Laboratories, L.P. | $1,118.43 | 2019-2025 | Nemluvio, Aklief |
| Abbvie INC. | $695.03 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $375.79 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $210.45 | 2023-2025 | |
| Vyne Pharmaceuticals INC. | $200.81 | 2021 | |
| Incyte Corporation | $140.08 | 2024-2025 | Opzelura |
| Dermavant Sciences, INC. | $125.84 | 2023-2024 | Vtama |
| Astrazeneca Pharmaceuticals LP | $124.98 | 2022 | |
| Pfizer INC. | $112.06 | 2020-2025 | |
| Journey Medical Corporation | $91.16 | 2023-2025 | |
| Leo Pharma INC. | $90.90 | 2025 | Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.25 | 2019-2025 | Cabtreo, Siliq |
| Epi Health, LLC | $28.17 | 2021 | |
| Lilly USA, LLC | $26.25 | 2022-2024 | Olumiant |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $25.58 | 2025 | Sotyktu |
| Organon LLC | $21.35 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $16.04 | 2024 | Zoryve |
| Genzyme Corporation | $14.71 | 2025 | |
| Amgen INC. | $11.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kiken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.